ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Haemophilia B Patients Switched to Recombinant Factor IX-Albumin Fusion Protein (rIX-FP): Ultrasound and Clinical Joint Assessment

G.F. Rivolta1, A. Coppola1, G. Quintavalle1, A. Matichecchia1, F. Riccardi1, R.M. Polo2, A. Tagliaferri1

1Regional Reference Centre for Haemophilia and Inherited Bleeding Disorders, University-Hospital of Parma, Parma, Italy, 2Orthopedic Department, University-Hospital of Parma, Parma, Italy

Abstract Number: PB1004

Meeting: ISTH 2020 Congress

Theme: Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical

Background: Prophylaxis is the only strategy to prevent the onset/progression of haemophilic arthropathy. The introduction of extended half-life (EHL) concentrates improved personalization and convenience of prophylaxis by reducing infusion frequency, especially in haemophilia B. However, few real-life data are available, particularly on joint assessment. Ultrasound (US) is useful to early detect and monitor arthropathy.

Aims: This study aims to collect data about joint status in patients with haemophila B switching to a EHL concentrate, rIX-FP.

Methods: At annual check-up joints were evaluated by physical examination (Haemophilia Joint Health Score in children; Gilbert score in adults) and by ultrasound scan (Haemophilia Early Arthropathy Detection with UltraSound, HEAD-US). The last available scores before switch and on rIX-FP treatment were compared, together with patients’ data (annualized bleeding rates [ABR], FIX trough levels, concentrate weekly dose) over comparable time periods on standard recombinant FIX (S-rFIX) and rIX-FP prophylaxis. Data mean±1 standard deviation are reported.

Results: Thirthy-six joints in 6 patients (5 severe, 1 moderate, age 31±12yrs) switched to rIX-FP (22±10mo) were evaluated. Results about ABR, FIX through levels, concentrate weekly dose, HEAD-US and orthopedic joint scores are shown in Tab 1.
HEAD-US score was free of abnormalities at both assessments on 22/36 (61%) joints. Six joints (46% of those with HEAD-US ≥1) had improvement on rIX-FP prophylaxis, due to reduction of synovial hypertrophy. Twenty-height joints showed orthopedic score 0 at both assessments. No joint had score improvement, whereas score increased in 2. Nine joints (25%) with HEAD-US ≥1 were negative at physical examination, whereas 2 (6%) had HEAD-US=0 but positive orthopedic scores.

Conclusions: Despite the limited patient sample, this study shows preserved joint status after switch to rIX-FP, associated with reduced rFIX consumption and sustained FIX trough levels. US scan reveals possible improvement of synovial hypertrophy and provides additional information about early abnormalities in joints negative at physical examination.

  rIX-FP S-rFIX p
ABR 0.8±1.6 0.1±0.1 –
FIX trough level (%) 10.8±1.9 3.9±1.4 0.002
FIX concentrate weekly dose (IU/kg) 35.6±12.1 89.8±22.3 0.001
HEAD-US scores 0.94±1.8 0.8±1.6 –
Orthopedic scores 0.31±0.7 0.25±0.6 –

[Table 1]

To cite this abstract in AMA style:

Rivolta GF, Coppola A, Quintavalle G, Matichecchia A, Riccardi F, Polo RM, Tagliaferri A. Haemophilia B Patients Switched to Recombinant Factor IX-Albumin Fusion Protein (rIX-FP): Ultrasound and Clinical Joint Assessment [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/haemophilia-b-patients-switched-to-recombinant-factor-ix-albumin-fusion-protein-rix-fp-ultrasound-and-clinical-joint-assessment/. Accessed October 1, 2023.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/haemophilia-b-patients-switched-to-recombinant-factor-ix-albumin-fusion-protein-rix-fp-ultrasound-and-clinical-joint-assessment/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley